<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Psychiatry</journal-id>
<journal-title>Frontiers in Psychiatry</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Psychiatry</abbrev-journal-title>
<issn pub-type="epub">1664-0640</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fpsyt.2022.980516</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Psychiatry</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>SPECT findings on neuropsychiatric symptoms caused by nitrous oxide abuse</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Wang</surname> <given-names>Li</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1848885/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Yin</surname> <given-names>Lijie</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1767758/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Wang</surname> <given-names>Qian</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Wang</surname> <given-names>Renbin</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Liu</surname> <given-names>Zunjing</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/407191/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Dong</surname> <given-names>Mingrui</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Duan</surname> <given-names>Xiaohui</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1699234/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Zheng</surname> <given-names>Yumin</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1847054/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Hong</surname> <given-names>Wen</given-names></name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Liu</surname> <given-names>Fang</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x0002A;</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Tie</surname> <given-names>Changle</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="corresp" rid="c002"><sup>&#x0002A;</sup></xref>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Neurology, The First Hospital of Tsinghua University</institution>, <addr-line>Beijing</addr-line>, <country>China</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Neurology, China-Japan Friendship Hospital</institution>, <addr-line>Beijing</addr-line>, <country>China</country></aff>
<aff id="aff3"><sup>3</sup><institution>Department of Nuclear Medicine, China-Japan Friendship Hospital</institution>, <addr-line>Beijing</addr-line>, <country>China</country></aff>
<aff id="aff4"><sup>4</sup><institution>Department of Radiology, China-Japan Friendship Hospital</institution>, <addr-line>Beijing</addr-line>, <country>China</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Yuka Kotozaki, Iwate Medical University, Japan</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Richa Tripathi, All India Institute of Medical Sciences Gorakhpur, India; Hiroshi Matsuda, Southern TOHOKU Research Institute for Neuroscience, Japan</p></fn>
<corresp id="c001">&#x0002A;Correspondence: Fang Liu <email>fangliu23&#x00040;163.com</email></corresp>
<corresp id="c002">Changle Tie <email>tiechangle&#x00040;163.com</email></corresp>
<fn fn-type="other" id="fn001"><p>This article was submitted to Addictive Disorders, a section of the journal Frontiers in Psychiatry</p></fn></author-notes>
<pub-date pub-type="epub">
<day>17</day>
<month>11</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>13</volume>
<elocation-id>980516</elocation-id>
<history>
<date date-type="received">
<day>28</day>
<month>06</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>21</day>
<month>10</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2022 Wang, Yin, Wang, Wang, Liu, Dong, Duan, Zheng, Hong, Liu and Tie.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Wang, Yin, Wang, Wang, Liu, Dong, Duan, Zheng, Hong, Liu and Tie</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license> </permissions>
<abstract>
<sec>
<title>Objective</title>
<p>The aim of the study was to investigate the clinical, neuropsychological, and regional cerebral blood flow (rCBF) perfusion changes in patients with neuropsychiatric symptoms caused by nitrous oxide (N<sub>2</sub>O) abuse.</p>
</sec>
<sec>
<title>Methods</title>
<p>A total of 16 patients with neuropsychiatric symptoms caused by nitrous oxide abuse were recruited for this study. The study was carried out in the withdrawal phase of N<sub>2</sub>O abuse. A 925&#x02013;1110 MBq <sup>99m</sup>Tc-ECD was administered intravenously. SPECT/CT images were collected with a low-energy and high-resolution collimator. The region uptake statistics of different brain regions of interest between patients with N<sub>2</sub>O abuse and normal people of the databases for younger subjects from the Scenium DB Comparison software were calculated automatically.</p>
</sec>
<sec>
<title>Results</title>
<p>The clinical manifestations of the 16 patients with neuropsychiatric symptoms were mood lability, anxiety, hallucination, delusion, agitation, confusion, and other psychiatric symptoms. In addition, 15 of the patients also complained of memory decline; 14 patients manifested numbness or paresthesia; 14 patients developed limb weakness, and their motor impairments were more severe in the lower limbs than in the upper limbs; and eight patients had urinary and defecation disturbances. In the neuropsychological examination, the BPRS score was 54.69 &#x000B1; 11.48, the HAMD score was 30.00 &#x000B1; 11.06, the HAMA score was 18.06 &#x000B1; 5.77, the MMSE score was 28.06 &#x000B1; 2.29, and the MoCA score was 25.06 &#x000B1; 3.40. SPECT showed hypoperfusion in the frontal and temporal lobes, which is consistent with the clinical findings.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>This was the first study to demonstrate the obvious effect of N<sub>2</sub>O abuse on CBF in patients with neuropsychiatric symptoms. CBF perfusion imaging is helpful to detect the changes in the local brain functional activity in patients with N<sub>2</sub>O abuse.</p>
</sec></abstract>
<kwd-group>
<kwd>neuropsychiatric symptoms</kwd>
<kwd>neuropsychological</kwd>
<kwd>regional cerebral blood flow</kwd>
<kwd>nitrous oxide abuse</kwd>
<kwd>SPECT</kwd>
</kwd-group>
<counts>
<fig-count count="2"/>
<table-count count="5"/>
<equation-count count="1"/>
<ref-count count="20"/>
<page-count count="8"/>
<word-count count="4053"/>
</counts>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="s1">
<title>Introduction</title>
<p>The Global Drug Survey 2019, which was conducted in more than 30 countries, revealed that nitrous oxide (N<sub>2</sub>O) was the 10th most popular substance among the studied population (<xref ref-type="bibr" rid="B1">1</xref>). N<sub>2</sub>O abuse for recreation is increasingly popular among Chinese adolescents and young adults, which leads to neurological and psychiatric complications (<xref ref-type="bibr" rid="B2">2</xref>). Subacute combined degeneration and peripheral neuropathy are identified as the most common neurological manifestations (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>). However, psychiatric and cognitive impairments caused by N<sub>2</sub>O abuse have not received much attention, and only case reports have been reported in the literature (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>).</p>
<p>Numerous studies have demonstrated significant mental health and behavioral comorbidities among patients who are inhalant abusers. Inhalant abusers are more likely to have an episode of major depression (<xref ref-type="bibr" rid="B7">7</xref>) and suicidality (<xref ref-type="bibr" rid="B8">8</xref>) and are at an increased risk of drug abuse problems in future (<xref ref-type="bibr" rid="B9">9</xref>). Functional imaging has proven to be very sensitive in detecting cerebral blood flow and metabolism derangement early in the course of drug addiction (<xref ref-type="bibr" rid="B10">10</xref>). This work focuses on single-photon emission computed tomography (SPECT) findings in patients with neuropsychiatric symptoms caused by N<sub>2</sub>O abuse.</p>
</sec>
<sec sec-type="methods" id="s2">
<title>Methods</title>
<sec>
<title>Subjects</title>
<p>A total of 16 patients who exhibited neuropsychiatric symptoms caused by N<sub>2</sub>O abuse between February 2018 and August 2020 were enrolled. The enrollment criteria for this study are as follows: (1) Patients with a history of N<sub>2</sub>O inhaling; (2) patients whose conditions comply with the diagnostic criteria of inhalant-related disorders, as coded according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-V); and (3) patients with a Brief Psychiatric Rating Scale (BPRS) score &#x0003E;35 points. The exclusion criteria of the study are as follows: patients with neuropsychiatric symptoms caused by other diseases or mental disorders.</p>
<p>This study was approved by the Ethics Committee of the China&#x02013;Japan Friendship Hospital (trial number 2018-34-K25). Written informed consent was obtained from all the participants. This study was carried out in the withdrawal phase of N<sub>2</sub>O abuse.</p>
</sec>
<sec>
<title>Clinical data collection</title>
<p>All the patients underwent a standard neurologic examination conducted by a neurologist, who registered clinical data and performed neuroimaging studies and laboratory tests. The mental state examination and neuropsychological rating were assessed by a psychiatrist using the following measures: (1) Brief Psychiatric Rating Scale (BPRS), (2) Hamilton Depression Scale (HAMD), (3) Hamilton Anxiety Scale (HAMA), (4) Mini-Mental State Examination (MMSE), and (5) Montreal Cognitive Assessment (MoCA).</p>
</sec>
<sec>
<title>Single-photon emission computerized tomography (SPECT)</title>
<p>SPECT were performed using a conventional dual-head gamma camera system (Symbia T2, Siemens Medical Solutions, Germany) equipped with low-energy high-resolution parallel-hole collimators nearly at the same time as subjective assessment. All the patients were supplemented with methylcobalamin in hospitalization. Brain perfusion imaging was performed for 20 min, followed by an intravenous injection of a 925&#x02013;1110 MBq <sup>99m</sup>Tc ethyl cysteinate dimer (ECD) (radiochemical purity &#x0003E;95%, HTA Co. Ltd, Beijing, China) in a dimly lit and quiet room with the patients&#x00027; eyes closed. Projection images were acquired through a 20% window centered on the 140 keV peak. The scan time per view was 25 s, and the matrix was 256 &#x000D7; 256. Scenium DB Comparison software (from the Siemens <ext-link ext-link-type="uri" xlink:href="http://symbia.net">symbia.net</ext-link> Neurology software package) was used for neurological evaluations with SPECT/CT imaging, enabling the comparison of functional studies (SPECT) of a specific patient to a database composed of scans from confirmed normal individuals. Each SPECT image was anatomically standardized using the MNI template provided by SPM. Then, the count of each voxel was standardized to the mean voxel count of the whole brain using proportional scaling. Quantitative parametric analysis was performed by database comparison software like Scenium (we choose the databases for younger subjects to analyze SPECT/CT imaging of patients with N<sub>2</sub>O abuse), which provides powerful quantification tools for the assessment of SPECT/CT, performs a voxel-by-voxel evaluation of the abnormal regions, and automatically identifies anatomical regions of interest (ROIs). The neurology workflow provides voxel-based statistics displayed as an image volume and calculates ROI statistics by comparing the corresponding estimated normal population mean with the value observed in the patient. Each SPECT image was segmented into 18 regions of interest (ROI) automatically and calculated by Scenium DB Comparison software. The statistical difference in the average uptake value of each brain region was calculated automatically.</p>
<p>The statistic was calculated by means of equation:</p>
<disp-formula id="E1"><mml:math id="M1"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>c</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>P</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mtext>&#x000A0;</mml:mtext><mml:mi>V</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>u</mml:mi><mml:mi>e</mml:mi><mml:mtext>&#x000A0;&#x000A0;</mml:mtext><mml:mi>P</mml:mi><mml:mi>o</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mtext>&#x000A0;</mml:mtext><mml:mi>M</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>o</mml:mi><mml:mi>p</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mtext>&#x000A0;</mml:mtext><mml:mi>S</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi><mml:mi>a</mml:mi><mml:mi>r</mml:mi><mml:mi>d</mml:mi><mml:mtext>&#x000A0;</mml:mtext><mml:mi>D</mml:mi><mml:mi>e</mml:mi><mml:mi>v</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:mfrac></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula>
<p>A statistic &#x0003E;1.68 indicated an increase in local CBF perfusion, while that &#x0003C; -1.68 indicated a decrease in local CBF perfusion. A statistic was normal between &#x02212;1.68 and 1.68.</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>All continuous variables were presented as mean &#x000B1; standard deviation. After SPECT image reconstruction, database comparison software was used for automatic processing and analysis. In total, 18 brain regions (e.g., basal ganglia, central region, cerebellum, cingulate gyrus, frontal lobe, medial temporal lobe, occipital lobe, parietal lobe, and temporal lobe) were calculated automatically. The paired sample <italic>t</italic>-test was performed on left and right brain regions. One-way ANOVA, followed by the least significant difference (LSD) test, was used to compare the averages and variances among different brain regions. The &#x003C7;<sup>2</sup> test was used to compare the changes in regional cerebral blood flow (rCBF) in different brain regions, and a <italic>P</italic>-value &#x0003C; 0.05 was considered statistically significant.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec>
<title>Demographic and clinical features</title>
<p>In this study, there were eight male and eight female patients with an age of onset ranging between 18 and 29 (mean age 21.56 &#x000B1; 2.83) years old. The duration of N<sub>2</sub>O exposure varied from 3 to 36 (mean 17.88 &#x000B1; 11.23) months. The course of disease varied from 0.5 to 4 (mean 1.81 &#x000B1; 1.09) months. Nonmedical abuse of more than one substance was found in four patients. Abuse of both N<sub>2</sub>O and cannabinoids was found in cases 1, 7, 8, and 10. A total of eight patients self-medicated with methylcobalamin prior to their hospital admission.</p>
<p>Clinical features of N<sub>2</sub>O abuse resulting in neuropsychiatric disorders are provided in <xref ref-type="table" rid="T1">Table 1</xref>, including mood lability, anxiety, hallucination, delusion, agitation, confusion, and other psychiatric symptoms. In addition, 15 of the patients complained of memory decline; 14 patients manifested numbness or paresthesia; 14 patients developed limb weakness, with motor impairments found more severe in lower limbs than in upper limbs; and eight patients had urinary and defecation disturbances.</p>
<table-wrap position="float" id="T1">
<label>Table 1</label>
<caption><p>Clinical features of N<sub>2</sub>O abuse resulting in neuropsychiatric disorders.</p></caption>
<table frame="hsides" rules="groups">
<thead><tr>
<th valign="top" align="left"><bold>Clinical features</bold></th>
<th valign="top" align="center"><bold>Number of patients</bold></th>
<th valign="top" align="center"><bold>%</bold></th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Confusion</td>
<td valign="top" align="center">7</td>
<td valign="top" align="center">43.75</td>
</tr>
<tr>
<td valign="top" align="left">Hallucination</td>
<td valign="top" align="center">13</td>
<td valign="top" align="center">81.25</td>
</tr>
<tr>
<td valign="top" align="left">Delusion</td>
<td valign="top" align="center">11</td>
<td valign="top" align="center">68.75</td>
</tr>
<tr>
<td valign="top" align="left">Panic attacks</td>
<td valign="top" align="center">5</td>
<td valign="top" align="center">31.25</td>
</tr>
<tr>
<td valign="top" align="left">Bizarre behavior</td>
<td valign="top" align="center">6</td>
<td valign="top" align="center">37.50</td>
</tr>
<tr>
<td valign="top" align="left">Manic</td>
<td valign="top" align="center">1</td>
<td valign="top" align="center">6.25</td>
</tr>
<tr>
<td valign="top" align="left">Agitated</td>
<td valign="top" align="center">7</td>
<td valign="top" align="center">43.75</td>
</tr>
<tr>
<td valign="top" align="left">Anxiety</td>
<td valign="top" align="center">12</td>
<td valign="top" align="center">75.00</td>
</tr>
<tr>
<td valign="top" align="left">Mood lability</td>
<td valign="top" align="center">16</td>
<td valign="top" align="center">100.00</td>
</tr>
<tr>
<td valign="top" align="left">Suicide ideation</td>
<td valign="top" align="center">4</td>
<td valign="top" align="center">25.00</td>
</tr>
<tr>
<td valign="top" align="left">Forgetfulness</td>
<td valign="top" align="center">15</td>
<td valign="top" align="center">93.75</td>
</tr>
<tr>
<td valign="top" align="left">Numbness or paresthesias</td>
<td valign="top" align="center">14</td>
<td valign="top" align="center">87.50</td>
</tr>
<tr>
<td valign="top" align="left">Weakness</td>
<td valign="top" align="center">14</td>
<td valign="top" align="center">87.50</td>
</tr>
<tr>
<td valign="top" align="left">Urinary disorder</td>
<td valign="top" align="center">8</td>
<td valign="top" align="center">50.00</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Laboratory findings are given in <xref ref-type="table" rid="T2">Table 2</xref>. Vitamin B12 levels were normal (893.00 &#x000B1; 414.19 pmol/L) in the nine self-medicated patients with methylcobalamin before admission, and homocysteine levels were still high in four of these patients. Among the remaining nine patients who were unmedicated with methylcobalamin before admission, vitamin B12 levels (133.30 &#x000B1; 64.12 pmol/L) were low in four patients and low to normal in the remaining three patients. Homocysteine levels were high in all the unmedicated patients (62.07 &#x000B1; 38.73 &#x003BC;mol/L). Anemia was diagnosed in nine patients.</p>
<table-wrap position="float" id="T2">
<label>Table 2</label>
<caption><p>Laboratory findings of N<sub>2</sub>O abuse resulting in neuropsychiatric disorders.</p></caption>
<table frame="hsides" rules="groups">
<thead><tr>
<th/>
<th valign="top" align="center" colspan="2" style="border-bottom: thin solid #000000;"><bold>Unmedicated with methylcobalamine before admission (</bold><italic><bold>N</bold></italic> = <bold>7)</bold></th>
<th valign="top" align="center" colspan="2" style="border-bottom: thin solid #000000;"><bold>Self-medicated with methylcobalamine before admission (</bold><italic><bold>N</bold></italic> = <bold>9)</bold></th>
</tr>
<tr>
<th/>
<th valign="top" align="center"><bold>Mean &#x000B1; SEM</bold></th>
<th valign="top" align="center"><bold>Range</bold></th>
<th valign="top" align="center"><bold>Mean &#x000B1; SEM</bold></th>
<th valign="top" align="center"><bold>Range</bold></th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Vitamin B12 (133&#x02013;675 pmol/L)</td>
<td valign="top" align="center">133.30 &#x000B1; 64.12</td>
<td valign="top" align="center">76.00&#x02013;237.00</td>
<td valign="top" align="center">893.00 &#x000B1; 414.19</td>
<td valign="top" align="center">221.00&#x02013;1476</td>
</tr>
<tr>
<td valign="top" align="left">Homocysteine ( &#x02264; 15 &#x003BC;mol/L)</td>
<td valign="top" align="center">62.07 &#x000B1; 38.73</td>
<td valign="top" align="center">24.68&#x02013;128.56</td>
<td valign="top" align="center">18.50 &#x000B1; 13.06</td>
<td valign="top" align="center">8.00&#x02013;47.57</td>
</tr>
<tr>
<td valign="top" align="left">Hemoglobin (115&#x02013;150 g/L)</td>
<td valign="top" align="center">116.29 &#x000B1; 22.69</td>
<td valign="top" align="center">87.00&#x02013;158.00</td>
<td valign="top" align="center">131.56 &#x000B1; 22.42</td>
<td valign="top" align="center">103.00&#x02013;160.00</td>
</tr>
<tr>
<td valign="top" align="left">MCV (82&#x02013;100 fL)</td>
<td valign="top" align="center">92.20 &#x000B1; 6.33</td>
<td valign="top" align="center">81.70&#x02013;101.80</td>
<td valign="top" align="center">93.49 &#x000B1; 10.68</td>
<td valign="top" align="center">77.30&#x02013;112.7</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec>
<title>Neuropsychological rating scale</title>
<p>Data from the neuropsychological rating scale are listed in <xref ref-type="table" rid="T3">Table 3</xref>. The BPRS score was 54.69 &#x000B1; 11.48 (anxiety depression factor score was 3.88 &#x000B1; 0.47; the lacking active factor score was 3.11 &#x000B1; 0.82; thinking disturbance factor score was 2.91 &#x000B1; 1.23; activity factor score was 2.06 &#x000B1; 0.66; the hostility factor score was 2.98 &#x000B1; 1.17), self-knowledge impairment score was 2.88 &#x000B1; 0.96, inability to work score was 4.25 &#x000B1; 1.13, HAMD score was 30.00 &#x000B1; 11.06, HAMA score was 18.06 &#x000B1; 5.77, MMSE score was 28.06 &#x000B1; 2.29 (two patients scored &#x0003C; 27), and MoCA score was 25.06 &#x000B1; 3.40 (seven patients scored &#x0003C; 26).</p>
<table-wrap position="float" id="T3">
<label>Table 3</label>
<caption><p>Neuropsychological rating scale.</p></caption>
<table frame="hsides" rules="groups">
<thead><tr>
<th valign="top" align="left" colspan="2"><bold>Rating scale</bold></th>
<th valign="top" align="center"><bold>Score</bold></th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">BPRS factors</td>
<td valign="top" align="left">Anxiety depression factor</td>
<td valign="top" align="center">3.88 &#x000B1; 0.47</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">The lacking active factor</td>
<td valign="top" align="center">3.11 &#x000B1; 0.82</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">The thinking disturbance factor</td>
<td valign="top" align="center">2.91 &#x000B1; 1.23</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">Activity factor</td>
<td valign="top" align="center">2.06 &#x000B1; 0.66</td>
</tr>
<tr>
<td/>
<td valign="top" align="left">The hostility factor</td>
<td valign="top" align="center">2.98 &#x000B1; 1.17</td>
</tr>
<tr>
<td valign="top" align="left">BPRS score</td>
<td/>
<td valign="top" align="center">54.69 &#x000B1; 11.48</td>
</tr>
<tr>
<td valign="top" align="left">HAMD</td>
<td/>
<td valign="top" align="center">30.00 &#x000B1; 11.06</td>
</tr>
<tr>
<td valign="top" align="left">HAMA</td>
<td/>
<td valign="top" align="center">18.06 &#x000B1; 5.77</td>
</tr>
<tr>
<td valign="top" align="left">MMSE</td>
<td/>
<td valign="top" align="center">28.06 &#x000B1; 2.29</td>
</tr>
<tr>
<td valign="top" align="left">MoCA</td>
<td/>
<td valign="top" align="center">25.06 &#x000B1; 3.40</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec>
<title>SPECT studies</title>
<p>Regional uptake statistics of the <sup>99<italic>m</italic></sup>TC-ECD between patients and normal people of the same age-group from the background software database are given in <xref ref-type="table" rid="T4">Table 4</xref>. No statistical significance was found in the <italic>t</italic>-test results of left and right uptake statistics (<italic>P</italic> &#x0003E; 0.05). No significant difference was found between brain regions (<italic>F</italic> = 5.919, <italic>P</italic> &#x0003C; 0.01). Significant differences were identified in the changes in rCBF in different brain regions (<italic>P</italic> &#x0003C; 0.01). Although brain MRI was normal in all patients, SPECT showed hypoperfusion in the frontal lobe (9/16, 56.25%) and the temporal lobe (12/16, 75.00%), which is consistent with the clinical findings (<xref ref-type="table" rid="T5">Table 5</xref>, <xref ref-type="fig" rid="F1">Figures 1</xref>, <xref ref-type="fig" rid="F2">2</xref>).</p>
<table-wrap position="float" id="T4">
<label>Table 4</label>
<caption><p>Regional uptake statistics of <sup>99m</sup>TC-ECD between patients and normal people of the same age group.</p></caption>
<table frame="hsides" rules="groups">
<thead><tr>
<th valign="top" align="left"><bold>ROI</bold></th>
<th valign="top" align="center"><bold>Left (Mean &#x000B1; SEM)</bold></th>
<th valign="top" align="center"><bold>Right (Mean &#x000B1; SEM)</bold></th>
<th valign="top" align="center"><bold>Average (Mean &#x000B1; SEM)</bold></th>
<th valign="top" align="center"><bold>Pearson correlation</bold></th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Basal ganglia</td>
<td valign="top" align="center">&#x02212;1.094, 2.519</td>
<td valign="top" align="center">&#x02212;1.200, 2.338</td>
<td valign="top" align="center">&#x02212;1.147, 2.391</td>
<td valign="top" align="center">0.942</td>
</tr>
<tr>
<td valign="top" align="left">Central region</td>
<td valign="top" align="center">0.350, 1.116</td>
<td valign="top" align="center">0.694, 0.990</td>
<td valign="top" align="center">0.522, 1.052</td>
<td valign="top" align="center">0.681</td>
</tr>
<tr>
<td valign="top" align="left">Cerebellum</td>
<td valign="top" align="center">&#x02212;0.638, 1.480</td>
<td valign="top" align="center">&#x02212;0.469, 1.940</td>
<td valign="top" align="center">&#x02212;0.553, 1.699</td>
<td valign="top" align="center">0.907</td>
</tr>
<tr>
<td valign="top" align="left">Cingulate and paracingulate gyri</td>
<td valign="top" align="center">0.59375, 1.885</td>
<td valign="top" align="center">0.543, 2.202</td>
<td valign="top" align="center">0.568, 2.017</td>
<td valign="top" align="center">0.747</td>
</tr>
<tr>
<td valign="top" align="left">Frontal lobe</td>
<td valign="top" align="center">&#x02212;1.575, 1.598</td>
<td valign="top" align="center">&#x02212;1.925, 1.593</td>
<td valign="top" align="center">&#x02212;1.743, 1.579</td>
<td valign="top" align="center">0.792</td>
</tr>
<tr>
<td valign="top" align="left">Medial temporal lobe</td>
<td valign="top" align="center">0.237, 1.862</td>
<td valign="top" align="center">&#x02212;0.018, 2.660</td>
<td valign="top" align="center">0.109, 2.262</td>
<td valign="top" align="center">0.912</td>
</tr>
<tr>
<td valign="top" align="left">Occipital lobe</td>
<td valign="top" align="center">&#x02212;0.793, 1.958</td>
<td valign="top" align="center">&#x02212;0.775, 1.688</td>
<td valign="top" align="center">&#x02212;0.784, 1.799</td>
<td valign="top" align="center">0.579</td>
</tr>
<tr>
<td valign="top" align="left">Parietal lobe</td>
<td valign="top" align="center">0.206, 2.063</td>
<td valign="top" align="center">0.400, 1.559</td>
<td valign="top" align="center">0.303, 1.801</td>
<td valign="top" align="center">0.800</td>
</tr>
<tr>
<td valign="top" align="left">Temporal lobe</td>
<td valign="top" align="center">&#x02212;2.05, 1.580</td>
<td valign="top" align="center">&#x02212;1.662, 0.879</td>
<td valign="top" align="center">&#x02212;1.856, 1.273</td>
<td valign="top" align="center">0.692</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap position="float" id="T5">
<label>Table 5</label>
<caption><p>Regional cerebral perfusion changes of N<sub>2</sub>O abuse resulting in psychiatric disorders.</p></caption>
<table frame="hsides" rules="groups">
<thead><tr>
<th valign="top" align="left"><bold>ROI</bold></th>
<th valign="top" align="center" colspan="3" style="border-bottom: thin solid #000000;"><bold>Numbers (%)</bold></th>
</tr>
<tr>
<th/>
<th valign="top" align="center"><bold>No change</bold></th>
<th valign="top" align="center"><bold>Increased perfusion</bold></th>
<th valign="top" align="center"><bold>Decreased perfusion</bold></th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Basal ganglia</td>
<td valign="top" align="center">10 (62.50%)</td>
<td valign="top" align="center">1 (6.25%)</td>
<td valign="top" align="center">5 (31.25%)</td>
</tr>
<tr>
<td valign="top" align="left">Central region</td>
<td valign="top" align="center">12 (75.00%)</td>
<td valign="top" align="center">4 (25.00%)</td>
<td valign="top" align="center">0 (0.00%)</td>
</tr>
<tr>
<td valign="top" align="left">Cerebellum</td>
<td valign="top" align="center">9 (56.25%)</td>
<td valign="top" align="center">2 (12.50%)</td>
<td valign="top" align="center">5 (31.25%)</td>
</tr>
<tr>
<td valign="top" align="left">Cingulate and paracingulate gyri</td>
<td valign="top" align="center">6 (37.50%)</td>
<td valign="top" align="center">6 (37.50%)</td>
<td valign="top" align="center">4 (25.00%)</td>
</tr>
<tr>
<td valign="top" align="left">Frontal lobe</td>
<td valign="top" align="center">7 (43.75%)</td>
<td valign="top" align="center">0 (0.0%)</td>
<td valign="top" align="center">9 (56.25%)</td>
</tr>
<tr>
<td valign="top" align="left">Medial temporal lobe</td>
<td valign="top" align="center">9 (56.25%)</td>
<td valign="top" align="center">4 (25.00%)</td>
<td valign="top" align="center">3 (18.75%)</td>
</tr>
<tr>
<td valign="top" align="left">Occipital lobe</td>
<td valign="top" align="center">8 (50.00%)</td>
<td valign="top" align="center">3 (18.75%)</td>
<td valign="top" align="center">5 (31.25%)</td>
</tr>
<tr>
<td valign="top" align="left">Parietal lobe</td>
<td valign="top" align="center">9 (56.25%)</td>
<td valign="top" align="center">4 (25.00%)</td>
<td valign="top" align="center">3 (18.75%)</td>
</tr>
<tr>
<td valign="top" align="left">Temporal lobe</td>
<td valign="top" align="center">4 (25.00%)</td>
<td valign="top" align="center">0 (0.0%)</td>
<td valign="top" align="center">12 (75.00%)</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption><p>SPECT images of Case 2, a 19-year-old man.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fpsyt-13-980516-g0001.tif"/>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption><p>SPECT standard regions of case 15, a 23-year-old woman.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fpsyt-13-980516-g0002.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>N<sub>2</sub>O is colloquially known as &#x0201C;hippy crack&#x0201D; or &#x0201C;laughing gas.&#x0201D; It is increasingly taken for recreational purposes for its euphoric and relaxing effects and hallucinogenic properties. The abuse of N<sub>2</sub>O is a significant public health concern, which predominantly affects adolescents. Although the subacute combined degeneration of the spinal cord and peripheral neuropathy caused by N<sub>2</sub>O abuse are gradually concerned as the most common neurological damage (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>), psychiatric symptoms and cognitive dysfunction caused by N<sub>2</sub>O abuse have not received much attention (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B12">12</xref>). All the patients enrolled in this study consumed large amounts of N<sub>2</sub>O for a long time before the onset of neuropsychiatric symptoms. Their psychiatric symptoms included emotional symptoms (e.g., mania, depression, anxiety, and fear), psychotic symptoms (hallucinations and delusions), personality changes, and impulsive and aggressive behavior, in line with previous reports (<xref ref-type="bibr" rid="B13">13</xref>). The anxiety depression factor score was the highest in the BPRS score, which was consistent with the HAMD and HAMA scores, suggesting that the patients must have symptoms of anxiety and depression. Thinking factors (e.g., disorder of concept, exaggeration, hallucinations, and abnormal thinking content) have high factor scores, indicating that patients with positive psychotic symptoms are prominent, and affect self-awareness and ability to work and study. The lack of vitality factor scores in the BPRS scores indicates that in addition to the positive symptoms, negative symptoms are also more prominent. This is not reported in previous studies. The relationship between negative symptoms and long-term prognosis and brain function needs further follow-up.</p>
<p>Of the 16 patients, 15 patients and their families complained of unresponsiveness and decreased memory, and seven of them had a MoCA score &#x0003C; 26, indicating that there was a decline in cognitive function (e.g., memory loss, inattention, and executive function decline). Both psychiatric symptoms and cognitive dysfunction result in the decline of work and life abilities.</p>
<p>Chronic N<sub>2</sub>O poisoning is related to the interference of vitamin B12, inactivates methionine synthase, interferes with myelin anabolic metabolism, and also results in the accumulation of homocysteine (<xref ref-type="bibr" rid="B14">14</xref>). High levels of homocysteine cause oxidative stress and mitochondrial dysfunction, leading to nerve demyelination (<xref ref-type="bibr" rid="B15">15</xref>). Homocysteine activates N-methyl-D-aspartate receptors on neuronal cell membranes and induces calcium ions to flow into neurons and mitochondrial calcium overload, eventually leading to neuronal necrosis and apoptosis (<xref ref-type="bibr" rid="B16">16</xref>). Of the 16 patients. 11 patients in this study had elevated serum homocysteine levels and only four of them had decreased levels of vitamin B12, which may be related to the nine patients who had self-medicated with methylcobalamin before their visit to our department. This result suggests that elevated serum levels of homocysteine is a more sensitive indicator than decreased serum levels of vitamin B12 for diagnosis (<xref ref-type="bibr" rid="B14">14</xref>).</p>
<p>Although the brain MRI of the patients enrolled in this study showed that the brain structure was normal, rCBF changes were different in different brain regions in this study. Local decreased or increased blood perfusion was observed in several brain regions, rather than diffuse decreased blood perfusion. The main findings were hypoperfusion in the frontal lobe and the temporal lobe, which is in accordance with the clinical manifestations of mental behavior abnormalities and cognitive functional decline caused by N<sub>2</sub>O abuse.</p>
<p>Similar to ketamine, N<sub>2</sub>O, as an NMDAR antagonist, can reduce the signaling of excitatory glutamate neurons, change the structure and function of hippocampal synapses, and cause learning and memory disorders. Short-term N<sub>2</sub>O exposure can cause reversible vacuolation of neurons, while long-term abuse can lead to neuron death (<xref ref-type="bibr" rid="B17">17</xref>). Psychiatric symptoms and cognitive decline in these patients may be dominated by this injury mechanism. Therefore, it is worth further studying the changes in neurotransmitters caused by N<sub>2</sub>O abuse and how they affect the learning and memory functions of adolescents.</p>
<p>In the treatment of patients with neuropsychiatric symptoms caused by N<sub>2</sub>O abuse, in addition to supplying vitamin B12 for nerve repair, we should also perform neuropsychological testing in time to strengthen interventions for mental symptoms and enhance patient compliance, which will not only improve the prognosis of patients but also help prevent relapse (<xref ref-type="bibr" rid="B18">18</xref>).</p>
<p>Previous studies have shown that N<sub>2</sub>O abuse may induce manic relapse in patients with mood disorders (<xref ref-type="bibr" rid="B19">19</xref>). The occurrence of psychiatric symptoms observed in this study is consistent with the clinical characteristics of substance-induced mental disorders, which indicate that N<sub>2</sub>O abuse can induce mental disorders. Future studies should expand the sample size to further explore the pathogenesis and disease characteristics of N<sub>2</sub>O-induced mental disorders.</p>
<p>As most of the patients reported initiation of N<sub>2</sub>O use in late adolescence or early adulthood, which involves risks to their still developing brain (<xref ref-type="bibr" rid="B20">20</xref>), education about N<sub>2</sub>O abuse is necessary to prevent impaired brain development. Follow-up and further investigation of the possible effects of N<sub>2</sub>O on brain development in young people will lead to meaningful prevention strategies.</p>
<p>The limitation of our study is the small sample size. We will continue to collect cases and expand the sample size to further explore the pathogenesis of N<sub>2</sub>O-induced neuropsychiatric damage.</p>
</sec>
<sec sec-type="conclusions" id="s5">
<title>Conclusion</title>
<p>This was the first study to demonstrate the obvious effect of N<sub>2</sub>O abuse on CBF in patients with neuropsychiatric symptoms. CBF perfusion imaging is helpful in detecting the changes in rCBF in patients with N<sub>2</sub>O abuse, thus indicating changes in local brain functional activity in an early stage.</p>
</sec>
<sec sec-type="data-availability" id="s6">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.</p>
</sec>
<sec id="s7">
<title>Ethics statement</title>
<p>The study involving human participants was approved by the Medical Ethics Committee of China&#x02013;Japan Friendship Hospital. The trial number is: 2018-34-K25. Written informed consent was obtained from all the participants or his/her parents/legal representatives (for participant under 18 years old).</p>
</sec>
<sec id="s8">
<title>Author contributions</title>
<p>FL and CT: have full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. LW, FL, and CT: study concept and design and study supervision. LW, QW, MD, and XD: acquisition of data. CT, RW, and ZL: neuropsychological rating. WH: magnetic resonance imaging. LY and YZ: SPECT/CT imaging. LW, QW, and FL: analysis and interpretation of data. LW and FL: drafting of the manuscript. LW: funding acquisition. All authors critical revision of the manuscript for important intellectual content. All authors read and approved the final manuscript.</p>
</sec>
<sec sec-type="funding-information" id="s9">
<title>Funding</title>
<p>This study was supported by research grants from the First Hospital of Tsinghua, University Pilot Funds (LH-02).</p>
</sec>
<sec sec-type="COI-statement" id="conf1">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s10">
<title>Publisher&#x00027;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</body>
<back>
<ack><p>We are grateful to all the patients for their participation in this study.</p>
</ack>

<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<citation citation-type="web"><person-group person-group-type="author"><name><surname>Barratta</surname> <given-names>MJ</given-names></name> <name><surname>Hughes</surname> <given-names>CE</given-names></name> <name><surname>Ferris</surname> <given-names>JA</given-names></name> <collab>Global Drug Survey</collab></person-group> (<year>2019</year>). <source>The GDS Core Research Team, London, UK</source>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.globaldrugsurvey.com/wp-content/themes/globaldrugsurvey/results/GDS2019-Exec-Summary.pdf">https://www.globaldrugsurvey.com/wp-content/themes/globaldrugsurvey/results/GDS2019-Exec-Summary.pdf</ext-link> (accessed May 19, 2019).</citation>
</ref>
<ref id="B2">
<label>2.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garakani</surname> <given-names>A</given-names></name> <name><surname>Jaffe</surname> <given-names>RJ</given-names></name> <name><surname>Savla</surname> <given-names>D</given-names></name> <name><surname>Welch</surname> <given-names>AK</given-names></name> <name><surname>Protin</surname> <given-names>CA</given-names></name> <name><surname>Bryson</surname> <given-names>EO</given-names></name> <etal/></person-group>. <article-title>Neurologic, psychiatric, and other medical manifestations of nitrous oxide abuse: a systematic review of the case literature</article-title>. <source>Am J Addict.</source> (<year>2016</year>) <volume>25</volume>:<fpage>358</fpage>&#x02013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1111/ajad.12372</pub-id><pub-id pub-id-type="pmid">27037733</pub-id></citation></ref>
<ref id="B3">
<label>3.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alt</surname> <given-names>RS</given-names></name> <name><surname>Morrissey</surname> <given-names>RP</given-names></name> <name><surname>Gang</surname> <given-names>MA</given-names></name> <name><surname>Hoffman</surname> <given-names>RS</given-names></name> <name><surname>Schaumburg</surname> <given-names>HH</given-names></name></person-group>. <article-title>Severe myeloneuropathy from acute high-dose nitrous oxide (N<sub>2</sub>O) abuse</article-title>. <source>J Emerg Med.</source> (<year>2011</year>) <volume>41</volume>:<fpage>378</fpage>&#x02013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/j.jemermed.2010.04.020</pub-id><pub-id pub-id-type="pmid">20605391</pub-id></citation></ref>
<ref id="B4">
<label>4.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>HT</given-names></name> <name><surname>Chu</surname> <given-names>CC</given-names></name> <name><surname>Chang</surname> <given-names>KH</given-names></name> <name><surname>Liao</surname> <given-names>MF</given-names></name> <name><surname>Chang</surname> <given-names>HS</given-names></name> <name><surname>Kuo</surname> <given-names>HC</given-names></name> <etal/></person-group>. <article-title>Clinical and electrodiagnostic characteristics of nitrous oxide-induced neuropathy in Taiwan</article-title>. <source>Clin Neurophysiol.</source> (<year>2016</year>) <volume>127</volume>:<fpage>3288</fpage>&#x02013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.clinph.2016.08.005</pub-id><pub-id pub-id-type="pmid">27567448</pub-id></citation></ref>
<ref id="B5">
<label>5.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sethi</surname> <given-names>NK</given-names></name> <name><surname>Mullin</surname> <given-names>P</given-names></name> <name><surname>Torgovnick</surname> <given-names>J</given-names></name> <name><surname>Capasso</surname> <given-names>G</given-names></name></person-group>. <article-title>Nitrous oxide &#x02018;whippit&#x00027; abuse presenting with cobalmin responsive psychosis</article-title>. <source>J Med Toxicol.</source> (<year>2006</year>) <volume>2</volume>:<fpage>714</fpage>. <pub-id pub-id-type="doi">10.1007/BF03161175</pub-id><pub-id pub-id-type="pmid">18072118</pub-id></citation></ref>
<ref id="B6">
<label>6.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>T</given-names></name> <name><surname>Zhong</surname> <given-names>N</given-names></name> <name><surname>Jiang</surname> <given-names>H</given-names></name> <name><surname>Zhao</surname> <given-names>M</given-names></name> <name><surname>Chen</surname> <given-names>Z</given-names></name> <name><surname>Sun</surname> <given-names>H</given-names></name></person-group>. <article-title>Neuropsychiatric symptoms induced by large doses of nitrous oxide inhalation: a case report</article-title>. <source>Shanghai Arch Psychiatry.</source> (<year>2018</year>) <volume>30</volume>:<fpage>56</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.11919/j.issn.1002-0829.217084</pub-id><pub-id pub-id-type="pmid">29719360</pub-id></citation></ref>
<ref id="B7">
<label>7.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sakai</surname> <given-names>JT</given-names></name> <name><surname>Hall</surname> <given-names>SK</given-names></name> <name><surname>Mikulich-Gilbertson</surname> <given-names>SK</given-names></name> <name><surname>Crowley</surname> <given-names>TJ</given-names></name></person-group>. <article-title>Inhalant use, abuse, and dependence among adolescent patients: commonly comorbid problems</article-title>. <source>J Am Acad Child Adolesc Psychiatry.</source> (<year>2004</year>) <volume>43</volume>:<fpage>1080</fpage>. <pub-id pub-id-type="doi">10.1097/01.chi.0000132813.44664.64</pub-id><pub-id pub-id-type="pmid">15322411</pub-id></citation></ref>
<ref id="B8">
<label>8.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Freedenthal</surname> <given-names>S</given-names></name> <name><surname>Vaughn</surname> <given-names>MG</given-names></name> <name><surname>Jenson</surname> <given-names>JM</given-names></name> <name><surname>Howard</surname> <given-names>MO</given-names></name></person-group>. <article-title>Inhalant use and suicidality among incarcerated youth</article-title>. <source>Drug Alcohol Depend.</source> (<year>2007</year>) <volume>90</volume>:<fpage>81</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2007.02.021</pub-id><pub-id pub-id-type="pmid">17433572</pub-id></citation></ref>
<ref id="B9">
<label>9.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oussalah</surname> <given-names>A</given-names></name> <name><surname>Julien</surname> <given-names>M</given-names></name> <name><surname>Levy</surname> <given-names>J</given-names></name> <name><surname>Hajjar</surname> <given-names>O</given-names></name> <name><surname>Franczak</surname> <given-names>C</given-names></name> <name><surname>Stephan</surname> <given-names>C</given-names></name> <etal/></person-group>. <article-title>Global burden related to nitrous oxide exposure in medical and recreational settings: a systematic review and individual patient data meta-analysis</article-title>. <source>J Clin Med.</source> (<year>2019</year>) <volume>8</volume>:<fpage>551</fpage>&#x02013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.3390/jcm8040551</pub-id><pub-id pub-id-type="pmid">31018613</pub-id></citation></ref>
<ref id="B10">
<label>10.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Quintana</surname> <given-names>JC</given-names></name></person-group>. <article-title>Neuropsiquiatria: pet y spect</article-title>. <source>Revista Chilena de Radiolog</source>&#x000ED;<italic>a</italic>. (<year>2019</year>) <volume>8</volume>:<fpage>63</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.4067/S0717-93082002000200005</pub-id></citation>
</ref>
<ref id="B11">
<label>11.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lightfoot</surname> <given-names>E</given-names></name> <name><surname>Brownlie</surname> <given-names>D</given-names></name> <name><surname>Lightfoot</surname> <given-names>J</given-names></name></person-group>. <article-title>Nitrous oxide toxicity: when laughing gas is no laughing matter&#x02014;a discussion of two cases</article-title>. <source>Emerg Med Aust EMA.</source> (<year>2020</year>) <volume>32</volume>:<fpage>710</fpage>&#x02013;<lpage>1</lpage>. <pub-id pub-id-type="doi">10.1111/1742-6723.13538</pub-id><pub-id pub-id-type="pmid">32500626</pub-id></citation></ref>
<ref id="B12">
<label>12.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ehirim</surname> <given-names>EM</given-names></name> <name><surname>Naughton</surname> <given-names>DP</given-names></name> <name><surname>Petr&#x000F3;czi</surname> <given-names>A</given-names></name></person-group>. <article-title>No laughing matter: presence, consumption trends, drug awareness, and perceptions of &#x0201C;Hippy Crack&#x0201D; (nitrous oxide) among young adults in England</article-title>. <source>Front Psychiatry.</source> (<year>2018</year>) <volume>8</volume>:<fpage>312</fpage>. <pub-id pub-id-type="doi">10.3389/fpsyt.2017.00312</pub-id><pub-id pub-id-type="pmid">29403400</pub-id></citation></ref>
<ref id="B13">
<label>13.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cousaert</surname> <given-names>C</given-names></name> <name><surname>Heylens</surname> <given-names>G</given-names></name> <name><surname>Audenaert</surname> <given-names>K</given-names></name></person-group>. <article-title>Laughing gas abuse is no joke. An overview of the implications for psychiatric practice</article-title>. <source>Clin Neurol Neurosurg.</source> (<year>2013</year>) <volume>115</volume>:<fpage>859</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.clineuro.2013.04.004</pub-id><pub-id pub-id-type="pmid">23643142</pub-id></citation></ref>
<ref id="B14">
<label>14.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hathout</surname> <given-names>L</given-names></name> <name><surname>El-Saden</surname> <given-names>S</given-names></name></person-group>. <article-title>Nitrous oxide-induced B12 deficiency myelopathy: perspectives on the clinical biochemistry of vitamin B12</article-title>. <source>J Neurol Sci.</source> (<year>2011</year>) <volume>301</volume>:<fpage>1</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.jns.2010.10.033</pub-id><pub-id pub-id-type="pmid">21112598</pub-id></citation></ref>
<ref id="B15">
<label>15.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shandal</surname> <given-names>V</given-names></name> <name><surname>Luo</surname> <given-names>JJ</given-names></name></person-group>. <article-title>Clinical manifestations of isolated elevated homocysteine induced peripheral neuropathy in adults</article-title>. <source>J Clin Neuromuscul Dis.</source> (<year>2016</year>) <volume>17</volume>:<fpage>106</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1097/CND.0000000000000108</pub-id><pub-id pub-id-type="pmid">26905910</pub-id></citation></ref>
<ref id="B16">
<label>16.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname> <given-names>KJ</given-names></name> <name><surname>Shelton</surname> <given-names>KL</given-names></name></person-group>. <article-title>N-methyl-D-aspartate receptor channel blocker-like discriminative stimulus effects of nitrous oxide gas</article-title>. <source>J Pharmacol Exp Ther.</source> (<year>2015</year>) <volume>352</volume>:<fpage>156</fpage>&#x02013;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.114.218057</pub-id><pub-id pub-id-type="pmid">25368340</pub-id></citation></ref>
<ref id="B17">
<label>17.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jevtovic-Todorovic</surname> <given-names>V</given-names></name> <name><surname>Beals</surname> <given-names>J</given-names></name> <name><surname>Benshoff</surname> <given-names>N</given-names></name> <name><surname>Olney</surname> <given-names>JW</given-names></name></person-group>. <article-title>Prolonged exposure to inhalational anesthetic nitrous oxide kills neurons in adult rat brain</article-title>. <source>Neuroscience.</source> (<year>2003</year>) <volume>122</volume>:<fpage>609</fpage>&#x02013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2003.07.012</pub-id><pub-id pub-id-type="pmid">14622904</pub-id></citation></ref>
<ref id="B18">
<label>18.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaar</surname> <given-names>SJ</given-names></name> <name><surname>Ferris</surname> <given-names>J</given-names></name> <name><surname>Waldron</surname> <given-names>J</given-names></name> <name><surname>Devaney</surname> <given-names>M</given-names></name> <name><surname>Ramsey</surname> <given-names>J</given-names></name> <name><surname>Winstock</surname> <given-names>AR</given-names></name></person-group>. <article-title>Up: the rise of nitrous oxide abuse. An international survey of contemporary nitrous oxide use</article-title>. <source>J Psychopharmacol.</source> (<year>2016</year>) <volume>30</volume>:<fpage>395</fpage>. <pub-id pub-id-type="doi">10.1177/0269881116632375</pub-id><pub-id pub-id-type="pmid">26912510</pub-id></citation></ref>
<ref id="B19">
<label>19.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tym</surname> <given-names>MK</given-names></name> <name><surname>Alexander</surname> <given-names>J</given-names></name></person-group>. <article-title>Nitrous oxide induced manic relapse</article-title>. <source>Aust N Z J Psychiatry.</source> (<year>2011</year>) <volume>45</volume>:<fpage>1002</fpage>. <pub-id pub-id-type="doi">10.3109/00048674.2011.580454</pub-id><pub-id pub-id-type="pmid">21548861</pub-id></citation></ref>
<ref id="B20">
<label>20.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chien</surname> <given-names>WH</given-names></name> <name><surname>Huang</surname> <given-names>MC</given-names></name> <name><surname>Chen</surname> <given-names>LY</given-names></name></person-group>. <article-title>Psychiatric and other medical manifestations of nitrous oxide abuse: implications from case series</article-title>. <source>J Clin Psychopharmacol.</source> (<year>2019</year>) <volume>40</volume>:<fpage>80</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1097/JCP.0000000000001151</pub-id><pub-id pub-id-type="pmid">31809285</pub-id></citation></ref>
</ref-list> 
</back>
</article>